Praj Industries Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xbsbfph7x3qniub40iy1j6ia.pdf

Key Takeaways


Profitability Pressure: The GenX Drag and Execution Mix

Sachin Raole: "The plan, the way in which we are looking at got completely shifted by almost by one year. We were expecting something to happen by next year from achieving this kind of a capacity utilization. Maybe we'll have to wait for one more year. So instead of FY'27, we will see this full capacity utilization happening in FY28."

International Business: Record Revenue and the US Low-Carbon Bet

Sachin Raole: "This is the first order which we are executing. So, this is going to be our first commercial demonstration in the US market of this kind of an order which is meant for low carbon. And naturally, it will set a trend for that market."

Domestic Bioenergy: Ethanol Headwinds and the Brownfield Pivot

Ashish Gaikwad: "The diesel blending is going to be a little different than the petrol blending. The component that needs to go in there is isobutanol, not ethanol. Praj has the technology to produce isobutanol at scale."

CBG and Biogas: Infrastructure-Linked Growth


Technology Pipeline: SAF, Bioplastics, and the BioVerse

Ashish Gaikwad: "I'm really proud to share with all of you that in the country today, we have a real demo facility where on one side when you put ethanol, we can run continuously the plant to get the sustainable aviation fuel that is certified for usage in the airplanes."

Margins: Gross Margin Strength, Consolidated Drag


Guidance & Commitments

CommitmentSpecificsTimeline
GenX full capacity utilizationFull capacity utilization at the fabrication facilityFY28 (shifted from FY27)
US low-carbon ethanol project commissioningFirst commercial demonstration order commissionedBy end of FY26 (March)
2G ethanol plant target productionIndian Oil plant reaches target productionBy end of FY26 (March)
Contract asset reversalMost dispatches under CIP move out, reversing capital blockageDecember-January, within 2-3 months
Diesel blending trialsIsobutanol trials planned with OMCs and ARAINo date given; trials being planned
Bioplastics revenueFirm order and revenue from bioplastics technologyNo timeline; discussions ongoing, no order booked
Vision 2030Path will be revisited but vision unchanged; steadfast on diversified portfolioLong-term, no revised date given

Key Metrics

MetricQ2 FY26
Consolidated income from operations₹842 cr, vs ₹816 cr in Q2 FY25
Profit before tax₹29.61 cr, vs ₹74.44 cr in Q2 FY25
Profit after tax₹19.28 cr, vs ₹53.8 cr in Q2 FY25
Effective tax rate35%, vs 37% for H1 FY26
Export revenue share46% of total revenue
Revenue mix64% bioenergy, 26% engineering, 10% PHS
Order intake₹810 cr, 73% domestic
Order intake mix71% bioenergy, 16% engineering, 13% PHS
Order backlog₹4,420 cr, 65% domestic
Cash in hand₹437 cr as of Sep 30, 2025
GenX fixed cost₹8.5–9 cr per month
H1 FY26 order intake~₹1,600 cr, vs ~₹1,800 cr in H1 FY25 (per an analyst's math)
Domestic ethanol orders in Q2~₹300 cr out of total ₹810 cr order intake
Forex gain~₹3 cr profit in Q2